|
Jul 30
|
Grifols Cuts Chinese Stake Value by €457 Million After Audit
|
|
Jul 29
|
Grifols receives expanded XEMBIFY® (immune globulin subcutaneous human-klhw) label in U.S., strengthening its Ig portfolio for patients
|
|
Jun 18
|
Grifols completes sale of a 20% equity stake in SRAAS and forges strategic alliance with Haier Group
|
|
Jun 17
|
Biotest wins FDA approval for plasma protein therapy
|
|
Jun 17
|
Grifols prepares for late-stage plans with plasma-derived medicines in 2024
|
|
Jun 17
|
Grifols’ Biotest receives FDA approval for innovative Yimmugo® immunoglobulin to treat primary immunodeficiencies
|
|
Feb 14
|
GRFS or ZTS: Which Is the Better Value Stock Right Now?
|
|
Feb 14
|
Grifols announces positive topline phase 3 fibrinogen clinical trial results
|
|
Jan 15
|
Here's Why Grifols (GRFS) is Poised for a Turnaround After Losing -31.55% in 4 Weeks
|
|
Jan 14
|
Grifols Says Haier Has Offered Reassurance on China Deal
|
|
Jan 14
|
Grifols says Haier Group still OK to buy stake in Shanghai RAAS
|
|
Jan 12
|
Grifols shares suffer worst week on record after short-seller report
|
|
Jan 12
|
Grifols Set for Biggest Weekly Drop Ever on Short Seller Tumult
|
|
Jan 11
|
Gotham Allegations ‘False,’ Grifols CEO Tells Investors
|
|
Jan 11
|
Grifols sees China stake sale going ahead despite Gotham City report
|
|
Jan 11
|
Grifols Faces Scrutiny of Billionaire Family’s Control
|
|
Jan 10
|
Gotham Slashes Grifols Short Position on Same Day as Selloff
|
|
Jan 10
|
Short Seller Attack Adds to Billionaire Grifols Dynasty Pain
|
|
Jan 10
|
Spain's Grifols to sue short-seller over critical report, shares jump
|
|
Jan 9
|
Factbox-What does the Gotham City report say about Grifols?
|